In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether US biotech firm Gilead Sciences’ Inc. (NASDAQ:GILD) new controversially high-prices hepatitis C drug Sovaldi (sofosbuvir) offers added benefit in comparison with the appropriate comparator therapy. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $79.32 moved to $79.50 on last trade day and at the end of the day closed at $77.71 . Company price to sales ratio in past twelve months was calculated as 0.74 and price to cash ratio as 17.42. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 5.16%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help patients lose weight and keep it off. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 0.30% in last trading session and ended the day on $6.68. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -20.48%.
Teva Pharmaceutical Industries Ltd.’s (ADR) (NYSE:TEVA) first-quarter earnings rose 8 percent, beating analyst estimates, as the company introduced generic drugs and a longer-acting version of the multiple sclerosis treatment Copaxone. Profit excluding some costs rose to $1 billion, or $1.22 a share, from $960 million, or $1.12, a year earlier, the Petach Tikva, Israel-based company said in a statement. Analysts predicted $1.20, the average of 20 estimates compiled by Bloomberg. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares moved down -2.18% in last trading session and was closed at $49.86 while trading in range of $49.08 – $50.94 – Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) year to date (YTD) performance is 25.34%.
Boston Scientific Corporation (NYSE:BSX) will present select abstracts and clinical data analyses pertaining to key issues in gastroenterology during Digestive Disease Week (DDW®) 2014, May 4-6 in Chicago. Data presentations will include the Boston Scientific SpyGlass™ Direct Visualization System, the Resolution™ Clip and the recently FDA cleared and CE marked Expect™ Slimline Needle for use in Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures. Boston Scientific Corporation (NYSE:BSX) weekly performance is -4.26%. On last trading day company shares ended up $12.81. Boston Scientific Corporation (NYSE:BSX) distance from 50-day simple moving average (SMA50) is -3.35%. Analysts mean target price for the company is $14.13.
Leave a Reply